RankAlpha logo
Back to Rankings

NMRA

Neumora TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The May 7, 2026 company update kept the core bullish setup intact: KOASTAL-2/-3 readout is still due in Q2 2026, NMRA-511 and NMRA-898 still have 2H26 data hooks, and cash of $147.1 million was guided to support operations into 3Q27 [#8-K-2026-05-07].
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -1.0.
What can break
KOASTAL-2 and KOASTAL-3 remain the dominant valuation drivers, so a weak or mixed Phase 3 readout could pressure the shares sharply.
Momentum
98
Value
41
Sentiment
74
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.80 · Bull $4.50 · Bear $0.80
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-15 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.14
Why
Momentum98 · Δ7d -1.0
Value41 · Δ7d +0.1
Sentiment74 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
98
34% active weight
Current posture
7d trendFlat
Δ7d
-1.0
Δ21d
-
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
74
33% active weight
Current posture
7d trendFlat
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 98.3 / Value 41.1 / Sentiment 73.5

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$337.22M
Beta
-
Shares Out
164.79M
P/E (TTM) · Derived
-1.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.58
Rev YoY
-
EPS YoY
+22.9%
Gross Margin
-
Op Margin
-
Net Debt
-$307.58M
Current Ratio
6.85
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology